PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Are your Companion Diagnostic Partners Ready?

The new In Vitro Diagnostic Medical Devices Regulation (IVDR), EU 2017/746, was published in the Official Journal of the European Union in May 2017 with full implementation by the date of application, 25th May 2022. It is envisaged that the new regulations will create a robust, regulatory framework which will be internationally recognised to improve clinical safety and improved market access. It appears, however, that the majority of stakeholders are not ready for the increased challenges of obtaining and maintaining compliance to the new requirements. Seamus Kearney and Maud Smyth from ARC Regulatory reckon that the lack of clarity in some key aspects of the text means that many Rx/CDx sponsors are unsure of how to develop or move forward with their compliance plans.

 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026